EUCTR2016-004091-21-GB进行中（未招募）1 期
ivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature - NEPTUNES
niversity College London0 个研究点目标入组 35 人开始时间: 2017年7月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion criteria for Pre-Screening (Assessment of ImS):
- •Metastatic castrate resistant prostate cancer.
- •Histologically confirmed prostate adenocarcinoma.
- •Patient has archival prostate cancer tissue available or has disease amenable to biopsy and is willing to undergo a new biopsy for assessment of ImS. Disease amenable to biopsy is:
- •oSoft tissue lesion meeting RECIST criteria that in the opinion of clinician and interventional radiologist is safe to biopsy, or
- •oBone lesion that is deemed suitable to biopsy by a suitably trained clinician.
- •Men =18 years.
- •Adequate venous access for administration of treatment and collection blood samples for exploratory biological samples.
- •Life expectancy of >6 months.
- •Has had or is having =1 line of systemic treatment for CRPC, or is currently having first line systemic treatment for mCRPC.
- •Reasonable expectation that the patient does currently, or will within the next 3 months, have progressive disease and fulfil all eligibility criteria for trial treatment
- •Inclusion Criteria for Main Study (Treatment):
- •Metastatic castrate resistant prostate cancer.
- •Histologically confirmed prostate adenocarcinoma.
- •Immunogenic signature positive disease
- •Patients with disease amenable to biopsy must be willing to have a new biopsy (if new biopsy was not required for assessment of ImS).
- •WHO performance status of 0-1.
- •Adequate haematological status.
- •Adequate liver and renal function.
- •Has had 1 line of systemic treatment for CRPC.
- •Documented prostate cancer progression within 6 months prior to screening for the Main Study
- •Ongoing androgen deprivation with serum testosterone <1.73 nmol/L.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Exclusion criteria for Assessment of ImS:
- •Any history of autoimmune disease, with the exception of patients with a history of autoimmune-related hyperthyroidism or hypothyroidism who are in remission or on a stable dose of thyroid-replacement hormone
- •Patients with prior allogeneic stem cell or solid organ transplantation
- •Active invasive malignancy in the previous 2 years excluding non-melanoma skin cancer.
- •History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan (History of radiation pneumonitis in the radiation field is permitted).
- •Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- •Patients with the following risk factors for bowel perforation:
- •oHistory of acute diverticulitis or intra-abdominal abcess in the last 3 years
- •oHistory of GI obstruction or abdominal carcinomatosis
- •History of grade =2 peripheral neuropathy.
- •Prior treatment with Sipuleucel-T, immune checkpoint targeting agents or other novel immune-oncology agents
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to enrolment, unstable arrhythmias, or unstable angina.
- •Patients with uncontrolled Type 1 diabetes mellitus. Patients controlled on a stable insulin regimen are eligible.
- •Patients with uncontrolled adrenal insufficiency.
- •Known active hepatitis B or C infection.
- •Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
- •Exclusion criteria for treatment:
- •All exclusion criteria to exclude patients from Assessment of ImS apply
- •Patients with risk factors for bowel perforation.
- •Patients must not have had systemic corticosteroid therapy (>10mg daily prednisone equivalent) for 14 days prior to study entry, or concomitant use of other immunosuppressive medications. The use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids (i.e., for adrenal insufficiency), and mineralocorticoids (e.g., fludrocortisone) is allowed.
- •Administration of a live, attenuated vaccine within 4 weeks prior to enrolment or anticipation that such a live, attenuated vaccine will be required during the study.
研究者
相似试验
进行中（未招募）
2 期
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureProstate CancerNCT03061539University College, London380
招募中
Unknown
Efficacy and Safety of Nivolumab+Ipilimumab or Pembrolizumab for Patients with Untreated Advanced or Recurrent Non-small Cell Lung Cancer; A Multicenter Retrospective Observational StudyJPRN-UMIN000049936Graduate School of Medicine, Osaka University450
进行中（未招募）
2 期
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate CancerProstate CancerNCT03637543Beth Israel Deaconess Medical Center29
已完成
不适用
ivolumab plus Ipilimumab versus existing immunotherapies in patients with PD-L1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis.PD-L1-positive previously untreated advanced non-small cell lung cancerJPRN-UMIN000039784Showa University School of Medicine4,011
已完成
3 期
CheckMate743JPRN-jRCT2080223370Bristol-Myers Squibb K.K.600